Cardio R&D Webinar: Phase III SHTG and Phase I ARO-Dimer-PA Data in 3Q:26

Research evidence excerpt

Cardio R&D Webinar: Phase III SHTG and Phase I ARO-Dimer-PA Data in 3Q:26

t (mil) 143.3

& -4 data to assess acute pancreatitis (AP) rate with 80% power if ~9 events and 90% 10Q as of May 1st + PFWs

if "teens" events occur. Arrowhead switched AP adjudication to the Revised Atlanta Market Cap. (mil) US$11,304.9

criteria, which was used in Ionis' CORE trials of TRYNGOLZA (olezarsen). We are Total Assets ($mil) NA

confident Arrowhead will report statistically significant reduction in TGs and AP rate, Avg Daily Vol (000) 1,777

Book Value/Share NA paving the way for label expansion into sHTG in late 2027 with blockbuster potential.

Net Cash Per Share US$6.47

Importantly, Dr. Steven Nissen of the Cleveland Clinic prefers REDEMPLO for fewer FY2Q:26 cash + $25M MDGL upfront less

AEs, greater potency and less frequent dosing. Participants who complete the 12-month debt

trials are eligible to enroll in the SHASTA-10 long-term safety study (NCT06822790). Div (ann) US$0.00

Fiscal Year End Sep

• ARO-DIMER-PA Topline Data in 3Q:26. ARO-DIMER-PA is Arrowhead’s first dual-

Price Performance - 1 Year trigger siRNA targeting both PCSK9 and APOC3. PCSK9 is the target of Novartis’

Leqvio and degrades LDL receptors on hepatocytes. Thus, PCSK9 inhibition enables USD

hepatocytes to remove LDL-C from the blood. Preclinical data in NHP showed that ARO- 90

DIMER-PA reduced both PCSK9 and APOC3 by 80% resulting in LDL-C reductions 80

of ~50%, non-HDL-C by >50%, and TG by >100mg/dl. Importantly, adding PCSK9 to 70

ARO-DIMER-PA offsets the LDL-C increases seen with APOC3 reduction caused by 50

TG lowering. The Phase I/IIa study is randomizing 78 adults with mixed hyperlipidemia 40

to escalating single and multiple doses of ARO-DIMER-PA. Ultimately, ARO-DIMER-PA 30